Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products.

ABSTRACT:

SUBMITTER: van Gerven J 

PROVIDER: S-EPMC6005602 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature